132results about How to "Symptoms improved" patented technology

The invention provides an animal bifidobacterium subsp. Lactis HNU329 with uric acid reducing ability and application thereof, the animal bifidobacterium subsp. Lactis HNU329 is preserved in Guangdong Microbiological Culture Collection Center GDMCC, the preservation address is Institute of Microbiology, Guangdong Academy of Sciences, on 5th floor, No. 59, No. 100 Courtyard, Xianlie Middle Road, Guangzhou, the preservation date is April 22, 2024, the preservation number is GDMCC No: 64546, and the preservation number is CGMCC No: 64546. The preparation method comprises the following steps of: classifying and naming Bifidobacteria animata subsp.lactis, and carrying out classification and naming on the Bifidobacteria animata subsp.lactis. The strain has good capacity of degrading nucleoside and purine in vitro, also shows good uric acid reducing capacity and anti-inflammatory capacity in animal model evaluation, and can regulate intestinal flora of mice with hyperuricemia and improve symptoms of hyperuricemia. The traditional Chinese medicine composition has no toxic or side effect, high safety and wide application prospect.

The application of the animal bifidobacterium subsp. Lactis BX-245 in relieving the inflammatory bowel disease is characterized in that the animal bifidobacterium subsp. Lactis BX-245 is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.26973. The invention also discloses an application of the animal bifidobacterium subsp. Lactis BX-245 in relieving the inflammatory bowel disease. The research aims at discussing the relieving effect of the animal bifidobacterium subsp. Lactis BX-245 on IBD mice induced by dextran sodium sulfate (DSS), and 6-week male C57BL / 6J mice which normally eat and drink water are randomly divided into a normal group (NC group), a model group (IBD group), a common yoghourt (FM group), an animal bifidobacterium subsp. Lactis BX-245 bacterial powder group (BX-245 group) and BX-245 yoghourt (BFM group). The relieving effect of the animal bifidobacterium subsp. Lactis BX-245 and the fermented milk of the animal bifidobacterium subsp. Lactis BX-245 on the symptom of the mouse inflammatory bowel disease is evaluated through weight change, immune factors, targeted metabonomics and metagenomics, and data support is provided for application of the animal bifidobacterium subsp. Lactis BX-245 in products.

The invention discloses construction and application of an oral gel drug delivery system based on a yeast microcapsule, and belongs to the field of new auxiliary materials and new dosage forms of pharmaceutical preparations, the drug delivery system is composed of budesonide nanoparticles, the yeast microcapsule and gel, budesonide nanoparticles are prepared from budesonide and a polylactic acid-glycolic acid copolymer through a water-in-oil emulsification evaporation technology, yeast cell wall microcapsules are formed after content of yeast powder is removed, and the budesonide-loaded yeast microcapsules are prepared from the yeast microcapsules and the budesonide nanoparticles through stirring, ultrasonic treatment and freeze drying methods. The yeast cell wall microcapsule without contents is used as a carrier, so that the medicine is protected from being degraded by gastric acid, and the intestinal immune response is regulated by targeting intestinal related lymphatic tissues (GALT). The gel prepared by combining pectin can prolong the residence time of the drug in the intestinal tract, realizes continuous release, reduces the whole-body side effect of budesonide, and improves the treatment efficiency.

The invention relates to the technical field of biological medicines, and particularly discloses application of gambogic acid in preparation of a medicine for treating ulcerative colitis. The gambogic acid provided by the invention can be used for preparing a programmed necrosis inhibitor and a medicine for treating ulcerative colitis, and the gambogic acid is beneficial to improving cell morphology, increasing cell viability and improving symptoms of ulcerative colitis caused by DSS. Chemical structure of gambogic acid: # imgabs0 #

The invention belongs to the technical field of traditional Chinese medicines, and discloses a traditional Chinese medicine composition for treating cervical spondylosis and a preparation method thereof. The traditional Chinese medicine composition is prepared from the following bulk drugs by weight: 45 to 55 g of pinellia ternate, 45 to 55 g of bighead atractylodes rhizome, 45 to 55 g of gastrodia elata, 45 to 55 g of uncaria, 45 to 55 g of poria cocos, 95 to 105 g of tuber fleeceflower stem, 95 to 105 g of red sage root, 45 to 55 g of Chinese angelica, 45 to 55 g of ligusticum wallichii, 45 to 55 g of peach kernel, 45 to 55 g of safflower, 45 to 55 g of red peony root, 45 to 55 g of notopterygium root, 45 to 55 g of turmeric, 25 to 35 g of pseudo-ginseng, 25 to 35 g of leech, 95 to 105 g of root of kudzu vine, 95 to 105 g of ginkgo leaf, 95 to 105 g of clematis root, 45 to 55 g of earthworm, 45 to 55 g of drynaria rhizome, the traditional Chinese medicine is quick in effect and high in curative effect, and the clinical total effective rate of the traditional Chinese medicine is 100% according to clinical practice statistics.

The invention provides a meibomian gland dysfunction treatment composition based on chlorella, the composition comprises sodium hyaluronate gel and drug-loaded chlorella powder, and the drug-loaded chlorella powder comprises chlorella and loaded drug components. The invention also provides a preparation method of the meibomian gland dysfunction treatment composition based on chlorella, which comprises the following steps: (1) dispersing a chlorella suspension in a sodium hydroxyethyl cellulose solution, and adding the medicinal components in the stirring process; (2) carrying out ultrasonic treatment and freeze drying to obtain drug-loaded chlorella powder; and (3) resuspending the drug-loaded chlorella powder, and adding sodium hyaluronate to form the gelatinous composition. The invention also provides application of the composition in preparation of medicines for treating meibomian glands. The composition not only can deliver active ingredients of the medicine in a targeted manner, but also can supplement lipid components lacking in meibomian glands, so that meibomian gland dysfunction is effectively treated.

The invention relates to the technical field of microorganisms, in particular to lactobacillus rhamnosus HZBX-05 and application thereof.The lactobacillus rhamnosus HZBX-05 is sent to the China General Microbiological Culture Collection Center on July 27th, 2023 to be preserved in the China General Microbiological Culture Collection Center, the preservation number of the lactobacillus rhamnosus HZBX-05 is CGMCC NO.987, and the preservation number of the lactobacillus rhamnosus HZBX-05 is CGMCC NO.989. The lactobacillus rhamnosus HZBX-05 is CGMCC NO.989. The lactobacillus rhamnosus HZBX-05 is CGMCC NO.989. The preservation number is CGMCC (China General Microbiological Culture Collection Center) NO.28035, and the address is Institute of Microbiology, Chinese Academy of Sciences, No.3, No.1 Yard, West Beichen Road, Chaoyang District, Beijing; the separated Lactobacillus rhamnosus HZBX-05 is continuously treated for 7 hours in a simulated gastric acid cholate environment, and the result shows that the HZBX-05 still has high survival rate, has the capability of being highly adsorbed to intestinal cells Caco-2 cells, has the capability of inhibiting various pathogenic bacteria, has immunoregulation and anti-inflammation effects, has the effect of resisting helicobacter pylori, and can be used for preparing an anti-inflammatory drug. The symptoms of female vaginitis can be improved.

The invention provides a traditional Chinese medicine composition. Compared with the prior art, the traditional Chinese medicine composition has the advantages that the traditional Chinese medicines are reasonably matched, so that all the components have the effect of synergistically improving insomnia, and uncomfortable symptoms such as exhaustion, cognitive competence impairment and irritability of insomnia patients are improved; meanwhile, a transcriptome sequencing technology is adopted, the effect of the traditional Chinese medicine composition on signal channels of patients with insomnia and mild and moderate senile dementia is analyzed and studied, and it is found that the traditional Chinese medicine composition can remarkably reverse disease-related channels on disease-related cell models, remarkably reverse insomnia disorder channels in neuronal cells and microglia cells, and remarkably reverse insomnia disorder channels in neuronal cells and microglia cells. Disorder pathways of mild and moderate senile dementia diseases are obviously reversed in neuronal cells and vascular endothelial cells; therefore, the traditional Chinese medicine composition can be used for improving insomnia and preventing and treating mild and moderate senile dementia, and the traditional Chinese medicine composition is prepared from medicinal and edible medicinal materials and is safe and reliable.

The invention provides a compound probiotic composition for improving allergic rhinitis as well as a preparation method and application thereof, and belongs to the technical field of biological preparations. Comprising a composite probiotic liquid, an auxiliary agent, a humectant and a thickening agent, wherein the composite probiotic liquid is composed of a composite bacterium fermentation liquid and probiotic substances, and the composite fermentation liquid is prepared by respectively fermenting saccharomyces boulardii, two bifidobacteria, lactobacillus reuteri, lactobacillus rhamnosus and streptococcus thermophilus. According to the compound probiotic composition, growth of probiotics is promoted through different probiotics, flora balance is adjusted and immunity is improved through mutual cooperation of the different probiotics, rhinitis symptoms are improved, meanwhile, components such as centipeda minima are added to serve as auxiliaries, and the effect of improving rhinitis symptoms is achieved. And the probiotics and the compound probiotics can achieve a synergistic effect to jointly improve the symptoms of the allergic rhinitis.

The invention discloses an application of inulin in preparation of a medicine for treating polycystic ovarian syndrome, especially the polycystic ovarian syndrome caused by high fat diet. Starting from the pathogenesis of the PCOS, research is carried out in the direction of'regulating host-intestinal dialogue by dietary fibers, promoting a tryptophan-quinolinic acid metabolic pathway to enhance an NAD + de novo synthesis pathway and improving PCOS oxidative stress and insulin resistance ', pathophysiology of the PCOS is researched from a brand new perspective, and the pathogenesis of a patient suffering from the PCOS is comprehensively researched in combination with metabonomics. And a new thought and a new target spot are provided for subsequent treatment.

The present invention proposes a Chinese medicine composition for treating allergic rhinitis, and a preparation method and application thereof, which belong to the field of pharmaceutical technology. Ag-graphene oxide is adsorbed on in vitro proliferated γδT cells, a Chinese medicine fermentation product obtained by fermentation and extraction of Xanthium sibiricum, Astragalus, Poria, Magnolia officinalis, and Mentha is prepared, berberine and quercetin are prepared into eutectic powder, the three are mixed and added into water, probiotics, carboxymethyl chitosan, poloxamer 407 and poloxamer 188 are added, and mixed evenly to prepare a Chinese medicine composition for treating allergic rhinitis, which has a good effect of improving allergic rhinitis, adopts a method of combining traditional Chinese and Western medicine, reduces inflammatory response, enhances the immune function of patients, improves the clinical symptoms of patients with allergic rhinitis, reduces the long-term recurrence rate, reduces the use of drugs, improves the quality of life, and reduces the risk of developing asthma, and has broad application prospects.

The invention discloses a pharmaceutical composition for treating hashimoto thyroiditis, and belongs to the technical field of traditional Chinese medicines. According to the pharmaceutical composition, astragalus membranaceus and codonopsis pilosula are used as monarch drugs to tonify qi, raise yang, tonify qi and strengthen body resistance; radix bupleuri, rhizoma cyperi and radix curcumae are used as ministerial drugs for soothing liver-qi stagnation, expelling evil, soothing liver-qi, regulating qi and harmonizing blood; humifuse euphorbia herb, lucid ganoderma and oldenlandia diffusa are used as adjuvant drugs for clearing away heat and toxic materials, reinforcing qi, nourishing blood and tranquilizing; the whole formula has the effects of tonifying qi, soothing the liver and clearing heat together. All the medicines are combined to effectively improve the symptoms of patients with hashimoto thyroiditis and reduce the thyroid autoantibody level. In addition, the pharmaceutical composition is good in safety, and a traditional Chinese and western medicine combined treatment strategy for hashimoto thyroiditis can be further popularized in the future.

The invention provides application of bifidobacterium adolescentis B-201 in preparation of products for relieving asthenopia and protecting eyesight, and belongs to the field of microbial fermentation. The bifidobacterium adolescentis B-201 provided by the invention has the preservation number of CGMCC (China General Microbiological Culture Collection Center) No.27234, and is preserved in the China General Microbiological Culture Collection Center (CGMCC) on April 27, 2023. The strain is subjected to culture fermentation and freeze drying to obtain bacterial powder, after auxiliary materials are added, the bacterial powder can be used for improving eye symptoms, increasing tear secretion amount, reducing ocular surface disease index scores and prolonging short-distance continuous eye using time, and the strain can be used for preparing products for relieving asthenopia and protecting eyesight.

The invention provides a resveratrol-loaded exosome and a preparation method thereof, and belongs to the technical field of biological medicine manufacturing. The preparation method of the resveratrol-loaded exosome comprises the following steps: performing 3D culture on human umbilical cord or hair follicle-derived mesenchymal stem cells under a low-oxygen condition, collecting supernate, and separating by a differential ultracentrifugation method to obtain the exosome of the mesenchymal stem cells; the method comprises the following steps: mixing a resveratrol solution containing a surfactant with the MSCs-Exos, and carrying out co-incubation and ultrafiltration to obtain the resveratrol loaded MSCs-Exos. According to the invention, the surfactant is added, so that not only are the entrapment rate and the drug loading rate of the MSCs-Exos loaded resveratrol greatly improved, but also the activity of the MSCs-Exos is maintained, the common effect of the MSCs-Exos and the resveratrol is fully exerted, and a synergistic effect is achieved. The resveratrol loaded MSCs-Exos disclosed by the invention has an effect of treating diabetes mellitus.

The invention discloses a pharmaceutical composition for insomnia (heart-spleen deficiency type) and hypomnesis and a preparation method of the pharmaceutical composition, and relates to the technical field of medicines.The composition is prepared from acanthopanax, astragalus membranaceus, lucid ganoderma, ginseng leaves, schisandra chinensis and gastrodia elata, the prescription mainly aims at the pathogenesis of insomnia caused by heart-spleen deficiency, the synergistic effect is achieved from multiple aspects, and the curative effect is good. The traditional Chinese medicine composition has the effect of treating insomnia caused by heart and spleen, and is a comprehensive and effective treatment scheme. Meanwhile, the effect of improving memory is also achieved. The prescription provided by the invention can be prepared into granules, oral preparations and the like. The pharmaceutical composition disclosed by the invention has a remarkable insomnia treatment effect which is superior to that of Western medicines such as eszopiclone tablets and estazolam tablets, the sleep inducing time is shortened, the sleep time of a patient with difficulty in falling asleep can be effectively shortened, meanwhile, the sleep time is optimally prolonged, the insomnia treatment effect is remarkable, and the situations of somnolence and non-awakening are avoided; the memory can also be improved. Meanwhile, no dependence is caused, and the insomnia is fundamentally treated.

The invention relates to the technical field of dental oral treatment, and discloses a repair method for treating periodontitis by using dental pulp stem cells, which comprises the following steps: S1, extracting dental pulp tissues from the oral cavity of a patient; s2, obtaining dental pulp stem cells; s3, culturing the dental pulp stem cells under specific conditions; s4, inducing the dental pulp stem cells to differentiate in the direction of osteogenesis, chondrogenesis or periodontal ligament cell formation; s5, transplanting the differentiated dental pulp stem cells to a periodontitis injury area of the patient, and using a biocompatible material; s6, applying a proper local stimulation means around the cell transplantation area; s7, by applying anti-inflammatory drugs locally or systemically, local immune response and inflammatory response are retarded, and repair and regeneration of periodontium are promoted. The problems that an existing treatment method is not lasting in effect, long in recovery period and the like are solved, the damaged periodontium is repaired through the dental pulp stem cells, the treatment effect can be remarkably improved, and the dental pulp stem cells have high clinical application value.

The invention discloses an HMPB / Mn3O4 nano-enzyme with multi-enzyme activity as well as a preparation method and application of the HMPB / Mn3O4 nano-enzyme. According to the nano-enzyme, HMPB with a hollow mesoporous structure is used as a carrier, and nano Mn3O4 is loaded on the inner surface and the outer surface of the HMPB through a self-assembly method; the HMPB / Mn3O4 nano-enzyme provided by the invention has good multi-enzyme activity, has no obvious cytotoxicity to NCM460 and RAW264.7 cells, can improve related symptoms of mice with DSS-induced ulcerative colitis, and is expected to become a novel potential medicine for treating ulcerative colitis.

The present invention relates to a sputum sample microbial flora and nucleic acid DNA preservation solution, including the following components by mass: 0.5-2 parts of trishydroxymethylaminomethane, 0.2-1 parts of mucus digestive agent, 3-6 parts of N-octylpyridinium bromide, 20-50 parts of fixative, 0.6-1.5 parts of auxiliary fixative, 1-2 parts of metal ion chelating agent, 0.5-3 parts of inorganic salt, the metal ion chelating agent includes at least 50wt% of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid; the auxiliary fixative is selected from at least one of sodium citrate and potassium citrate. The sputum sample microbial flora and nucleic acid DNA preservation solution using the technical solution of the present invention has the following advantages, can be stored and transported at room temperature for a long time, and is easy to operate; the sputum sample can be effectively liquefied by immersing the sputum sample in the protective solution, and the structural composition of the microorganism is stabilized at room temperature, protecting the diversity of its flora structure and DNA stability.

The invention discloses siRNA (small interfering Ribonucleic Acid) nanoparticles capable of efficiently targeting mononuclear phagocytes and mediated by intercellular effect of neutrophils as well as a preparation method and application of the siRNA nanoparticles. The siRNA nanoparticles comprise mesoporous silica nanoparticles carrying siRNA, and functional cell membranes over-expressing ICAM-1 ligands are wrapped outside the mesoporous silica nanoparticles carrying siRNA. Key sentinel cells (mononuclear phagocytes, MPs) for targeted mitochondrial DNA release to treat inflammatory responses caused by mtDNA. The efficient delivery of MPs is realized by using a functionalized cell membrane of an overexpressed ICAM-1 ligand to wrap nano-particles and by virtue of infiltration and rapid apoptosis of a large number of neutrophils in an inflammatory microenvironment and a process (cell burial effect) of specific phagocytosis of the neutrophils by the MPs. Compared with a traditional targeting scheme, the in-vitro targeting efficiency and the in-vivo targeting efficiency of the FCM-coated siNPs scheme are improved by 360% and 120% respectively. The siRNA is guided to target MPs, and the expression of STING is inhibited, so that the inflammatory reaction caused by mtDNA release is regulated and controlled, and an excellent anti-inflammatory curative effect is shown in an inflammatory model mouse.

One embodiment of the present invention discloses a method for implementing an application for improving mild cognitive impairment symptoms, comprising: a step of controlling a first training algorithm to be output to a user terminal in response to an input to the user terminal; when the first training algorithm is finished, controlling a second training algorithm to be output to the user terminal; a step of evaluating a user input for the first training algorithm and the second training algorithm when the second training algorithm ends; and a step of controlling a first visual display to be output to the user terminal based on a result of the evaluation.

The application discloses a method for controlling thiolated bacterial covalent colonization by chemical reaction and application. The application provides a unique in-situ chemical reaction mediated bacterial covalent colonization strategy. Through a simple one-step iminothiolane ring-opening reaction, the primary amino group on the surface of bacteria can be converted into a free thiol group under cell-compatible conditions. Surface thiolation can be used for modification of different strains, and the number of thiol groups introduced by each bacterium can be adjusted by different feeding ratios. These chemically reactive bacteria can spontaneously bind to the mucus layer through a sulfur-sulfur exchange reaction between the newly converted non-native thiol group on the surface of the bacteria and the disulfide bond contained in mucin without catalyst. The application converts the bacteria through surface modification to form a "living chemical reagent", and the surface-converted living reactive bacteria provide an unprecedented method for chemical control of bacterial colonization, which has guiding significance for the development of the next generation of living bacterial biological agents.

The invention discloses a traditional Chinese medicine atomizing agent with the effect of relieving heart diseases and a preparation method of the traditional Chinese medicine atomizing agent. The traditional Chinese medicine atomizing agent is prepared from the following traditional Chinese medicine raw materials: 3-10 g of ginseng, 4-15 g of pseudo-ginseng, 3-12 g of borneol, 8-15 g of ligusticum wallichii, 3-10 g of ginkgo leaves, 3-12 g of rohdea japonica roots, 2-6 g of venenum bufonis, 1-5 g of rhizoma curcumae longae, 5-8 g of long-noded pit viper and 10-15 g of mint. The selected traditional Chinese medicinal materials have the effects of promoting blood circulation to remove blood stasis, dredging channels and collaterals, tranquilizing mind by nourishing the heart and the like, the medicines rapidly enter the lung through the respiratory tract in an atomization mode and rapidly reach the heart through blood circulation, pertinence is high, rapid permeation and absorption of the medicines are achieved, the utilization rate of the medicines is increased, and the curative effect is rapidly exerted; the symptoms of patients with heart diseases are obviously improved, the body functions of the patients are regulated, and the recurrence rate of the diseases is reduced.

The invention relates to a squeezing preparation method of Fuzhuan tea lipid vesicle-like nanoparticles, which comprises the following steps: mixing Fuzhuan tea and ultrapure water in a mass ratio of (1: 6)-(1: 10), squeezing juice, passing through a 100-200-mesh filter screen, and squeezing to obtain a Fuzhuan tea stock solution; then, carrying out gradient centrifugation on the Fuzhuan tea stock solution to obtain supernate; and finally, carrying out centrifugal treatment on the supernatant at a relative centrifugal force higher than the highest relative centrifugal force of gradient centrifugation, and adding a standard phosphate buffer solution with the mass ratio of 1: 8-1: 10 to carry out resuspension precipitation, so as to obtain the Fuzhuan tea lipid vesicle-like nanoparticles. The invention also provides the Fuzhuan tea lipid vesicle-like nanoparticles obtained by using the method and application of the Fuzhuan tea lipid vesicle-like nanoparticles in treatment of ulcerative colitis. According to the invention, the seasonal influence of the preparation of the existing tea lipid vesicle-like nanoparticles is overcome, the cost is greatly reduced, the purity and quality are controllable, the problems of intestinal ecological imbalance such as mucosal epithelium repair, barrier homeostasis and the like can be solved, the safety is good, no side effect is generated, and a potential treatment mode is provided for the treatment of gastrointestinal diseases.

The application relates to the field of medicines, and discloses a preparation method of a Yi medicine composition, a decoction, granules, pills and a plaster, wherein the Yi medicine composition comprises, by weight, 20-50g of Bauhinia championii Benth, 20-60g of pilea pumila L., 20-40g of Dioscorea panthaica Prain et Buckl, 10-20g of Atractylodes lancea (Thunb.) DC, 20-30g of Foeniculum vulgare Mill, 10-25g of Amomum villosum Lour, 10-15g of Aucklandia lappa Decne, 9-15g of Punica granatum Linn, and 5-8g of Glycyrrhiza uralensis Fisch. The Yi medicine composition is mainly used for removing dampness and turbidity, promoting stagnation and benefiting the intestines, and has the treatment effects of regulating qi and relieving pain, expanding the middle and regulating qi, invigorating the spleen and promoting appetite, etc. The Yi medicine composition can effectively improve the symptoms of increased stool frequency, changed fecal quality, lassitude, poor appetite, etc. of patients with diarrhea caused by qi weakness and spleen and stomach dysfunction.

The application discloses a traditional Chinese medicine extract with antibacterial, anti-inflammatory and antipyretic effects and an active component self-assembled nanomaterial of the traditional Chinese medicine extract and application, wherein the polygonum capitatum extract and the active component self-assembled nanomaterial have the effects of inhibiting bacteria and relieving inflammation and can be used for treating atopic dermatitis. The in-vitro bacteriostatic experiment and animal experiment results verify that the polygonum capitatum extract and the active component self-assembled nanomaterial have the effects of resisting bacteria and inflammation and can effectively treat atopic dermatitis.

The invention discloses a traditional Chinese medicine composition for treating delayed absorption of qi-yin deficiency and lung collateral obstruction type pneumonia, a preparation and application. The traditional Chinese medicine composition is prepared from the following components in parts by weight: 10 to 15g of radix pseudostellariae, 10 to 15g of radix asparagi, 6 to 10g of cortex mori radicis, 6 to 10g of radix scutellariae, 6 to 10g of radix platycodonis, 6 to 10g of exocarpium citri grandis, 6 to 10g of bulbus fritillariae thunbergii, 10 to 15g of pericarpium trichosanthis, 10 to 15g of spica prunellae, 15 to 30g of raw oyster shell, 6 to 10g of earthworm, 10 to 15g of radix salviae miltiorrhizae, 6 to 10g of rhizoma curcumae and 6 to 10g of raw liquorice root. The traditional Chinese medicine composition is suitable for delayed absorption of pneumonia caused by deficiency of both qi and yin and obstruction of lung collaterals, and also can be used for treating deficiency-heat syndrome and deficiency-cold syndrome on the basis of the formula, so that the aim of treating due to symptoms is fulfilled. The prescription is used for treating both symptoms and root causes of patients with deficiency of both qi and yin, internal stagnation of phlegm and blood stasis and lung collateral obstruction in delayed absorption of pneumonia on the basis of the basic treatment principles of tonifying lung and yin, reducing phlegm and softening hard mass, and promoting blood circulation to remove meridian obstruction. Clinical research finds that the pharmaceutical composition can improve clinical symptoms of patients with delayed absorption of pneumonia and promote inflammatory absorption, and is relatively safe.

The invention discloses a composition capable of inhibiting neuraminidase activity and application of the composition. The composition is prepared from pericarpium citri reticulatae powder and platycodon grandiflorum powder. Wherein the mass ratio of the pericarpium citri reticulatae powder to the platycodon grandiflorum powder is 5: (2-4). The dried orange peel powder and the platycodon grandiflorum powder are used as main functional components, the dried orange peel powder and the platycodon grandiflorum powder are combined according to the ratio of 5: 3, and in-vitro tests prove that the prepared food has the properties of inhibiting neuraminidase activity and improving respiratory tract health.

The invention discloses a traditional Chinese medicine compound composition for treating phlegm clouding orifice type dementia and a preparation method and a using method thereof, and the traditional Chinese medicine compound composition is prepared from the following raw materials in parts by mass: 16-23 parts of bamboo juice, 11-17 parts of exocarpium citri rubrum, 6-12 parts of fructus alpiniae oxyphyllae, 12-18 parts of pheretima and 25-32 parts of caulis spatholobi. The traditional Chinese medicine is used for treating the turbid phlegm clouding orifice type dementia patient through a resuscitation inducing and phlegm reducing treatment method, the symptoms of the patient are obviously improved clinically, the compatibility is ingenious, the prescription is simple, only five medicines are adopted, the medicinal materials are easy to obtain and low in price, the requirement of a decoction technology is low, and the curative effect is obvious; the defects that western medicines are large in side effect and prone to generating drug resistance are overcome, and the advantages that traditional Chinese medicines are small in side effect and not prone to generating drug resistance are developed.

The present invention provides a bispecific chimeric antigen receptor (CAR) targeting CD37 and CD19, and related molecules, immune cells comprising the bispecific chimeric antigen receptor, compositions of the immune cells, and methods of using the same. The present invention also provides methods for treating diseases or disorders such as cancer.

A myoregulin inhibitor such as an antisense oligonucleotide against myoregulin or an anti-myoregulin antibody is used as an active ingredient of a prophylactic or therapeutic agent for a muscle disease such as muscular dystrophy, inclusion body myositis, amyotrophic lateral sclerosis, disused muscular atrophy, and sarcopenia.